Affinage

CSNK2A1

Casein kinase II subunit alpha · UniProt P68400

Length
391 aa
Mass
45.1 kDa
Annotated
2026-06-09
48 papers in source corpus 21 papers cited in narrative 21 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 5/6 claims corpus-supported (83%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

CSNK2A1 encodes the catalytic alpha subunit of the constitutively active, broadly pleiotropic serine/threonine protein kinase casein kinase II (CK2), which assembles in vivo as an alpha2beta2 holoenzyme but retains catalytic activity as a free monomeric alpha subunit (PMID:1527008). Genetic analysis in yeast established that the catalytic subunit is essential for viability only in conjunction with its paralog (alpha'), with the double deletion being lethal and the alpha subunit alone sufficient to rescue this lethality across species, while the alpha subunit additionally carries a non-redundant role in maintaining cell polarity, actin organization, and nuclear division (PMID:2196445, PMID:9488724). In mammals, CK2alpha phosphorylates a broad substrate repertoire to control proliferation, transcription, DNA damage repair, and metabolism: it phosphorylates SIRT6 at Ser338 to drive beta-catenin nuclear localization, proliferation, and DNA-repair-linked chemoresistance (PMID:27746184, PMID:34359939); it phosphorylates the transcriptional regulator MAX to favor C-MYC-MAX and beta-catenin-MAX heterodimers that activate HMGB1 and IL-6 promoters (PMID:37347224); and it phosphorylates HMGA2 and TOP2A in cancer contexts, with TOP2A phosphorylation downstream of SOX4-driven CSNK2A1 transcription (PMID:34115920, PMID:39931818). CK2alpha activity is directly enhanced by cholesterol binding, which couples it to phosphorylation of IGF2R at Ser2484 and a lipid-biosynthesis feedback loop, while OGT-mediated O-GlcNAcylation stabilizes the protein and H3K27 acetylation regulates its transcription (PMID:39547439, PMID:38289573, PMID:38290659). CK2alpha also promotes autophagy to confer chemoresistance and modulates apoptosis through AKT1 phosphorylation that is antagonized by competitive DUSP2 binding (PMID:37390887, PMID:38290659). In vivo, skeletal-muscle-specific ablation of CSNK2A1 disrupts neuromuscular junction integrity, oxidative metabolism, and autophagy, demonstrating a tissue-level requirement for the kinase (PMID:36552726).

Mechanistic history

Synthesis pass · year-by-year structured walk · 12 steps
  1. 1988 High

    Established that CSNK2A1's yeast ortholog encodes a 42 kDa CK2 catalytic alpha subunit whose loss alone is phenotypically silent, defining functional redundancy with a paralogous catalytic subunit.

    Evidence Gene cloning, sequencing, and gene disruption in S. cerevisiae

    PMID:3062376

    Open questions at the time
    • Did not test the double-knockout requirement
    • No substrate or mammalian function defined
  2. 1990 High

    Showed the two catalytic subunits are jointly essential for viability and that the function is evolutionarily conserved, since heterologous CK2 alpha rescues the lethal double deletion.

    Evidence cka1Δ cka2Δ double mutant phenotyping and cross-species complementation in yeast

    PMID:2196445

    Open questions at the time
    • Did not resolve which substrates underlie the essential function
    • Molecular basis of size/morphology arrest unknown
  3. 1992 High

    Resolved the quaternary biology of CK2 by demonstrating it functions as an alpha2beta2 holoenzyme in vivo but that free catalytic alpha is active and non-toxic, clarifying that the beta subunit is regulatory rather than required for catalysis.

    Evidence Biochemical purification and activity assays from rescued yeast strains

    PMID:1527008

    Open questions at the time
    • Did not define how beta modulates substrate selection in vivo
    • No structural detail
  4. 1998 High

    Distinguished a non-redundant role for the alpha catalytic subunit by linking its conditional loss specifically to cell polarity, actin organization, and nuclear division defects.

    Evidence Temperature-sensitive cka1 allele with actin/chitin staining and morphology analysis in yeast

    PMID:9488724

    Open questions at the time
    • Polarity substrates of CK2alpha not identified
    • Mechanism connecting kinase to actin/chitin unknown
  5. 1998 Medium

    Characterized the human CSNK2A1 gene architecture and a housekeeping-type promoter, framing it as a constitutively expressed gene.

    Evidence Genomic cloning, primer extension, reporter assay (consolidated with 1994 FISH mapping)

    PMID:8188256 PMID:9503018

    Open questions at the time
    • Promoter regulation by specific transcription factors not addressed
    • No link to expression dynamics in disease
  6. 2011 Medium

    Provided a defined substrate-level mechanism by showing CK2 phosphorylation of the E2 enzyme Cdc34 controls polyubiquitin chain handling, connecting CK2 to the ubiquitin system.

    Evidence In vitro kinase assay and genetic epistasis in yeast

    PMID:21453497

    Open questions at the time
    • Relevance to mammalian CSNK2A1 not tested
    • In vivo significance of the chain-attachment effect limited
  7. 2016 High

    Identified SIRT6 Ser338 as a direct CSNK2A1 phosphosite linking the kinase to Wnt/beta-catenin output and oncogenic proliferation/invasion.

    Evidence Reciprocal Co-IP, GST pull-down, in vitro kinase assay, and site-directed mutagenesis in breast cancer cells

    PMID:27746184

    Open questions at the time
    • Did not establish kinase-substrate stoichiometry in vivo
    • Generality across cell types limited
  8. 2021 Medium

    Extended the SIRT6-Ser338 axis to DNA damage repair and chemoresistance, and added HMGA2 as a cisplatin-inducible substrate, broadening CK2's role in cancer therapy response.

    Evidence Site-directed mutagenesis with in vivo tumor models; LC-MS/MS, Co-IP, and CX-4945 inhibition (two studies)

    PMID:34115920 PMID:34359939

    Open questions at the time
    • Single-lab findings per substrate
    • Direct phosphosite on HMGA2 not fully mapped
  9. 2022 High

    Demonstrated an in vivo tissue requirement by showing skeletal-muscle CSNK2A1 ablation impairs neuromuscular junctions, oxidative metabolism, and autophagy, and that CK2 alpha controls PC4 coactivator activity, tying the kinase to both physiology and transcription regulation.

    Evidence Conditional muscle knockout with electrophysiology/histology in mice; in vitro phosphorylation and transcription assays in S. pombe

    PMID:36012759 PMID:36552726

    Open questions at the time
    • Muscle substrates driving NMJ phenotype unknown
    • PC4 regulation tested in fission yeast, not mammalian cells
  10. 2023 Medium

    Expanded CK2's transcriptional and survival signaling roles by defining MAX phosphorylation-driven heterodimer switching and a DUSP2-mediated competitive brake on CK2-AKT1 signaling.

    Evidence Co-IP, promoter assays, competition binding, and apoptosis assays in cancer models

    PMID:37347224 PMID:37390887

    Open questions at the time
    • MAX phosphosite not mapped
    • Direct AKT1 phosphosite by CK2 not defined
  11. 2024 Medium

    Revealed multilayered regulation of CSNK2A1 itself — cholesterol-binding activation coupled to IGF2R Ser2484 phosphorylation and lipid feedback, OGT O-GlcNAcylation stabilizing the protein, and H3K27ac-driven transcription — linking the kinase to metabolic and epigenetic control of cancer.

    Evidence Direct binding and kinase assays, phosphoproteomics, Co-IP, and PDX models across HCC, CRC, and pancreatic cancer

    PMID:38289573 PMID:38290659 PMID:39547439

    Open questions at the time
    • Each regulatory layer shown in a single cancer context
    • Cholesterol-binding site on CSNK2A1 not structurally defined
  12. 2025 Medium

    Connected upstream transcriptional control (SOX4) to a downstream substrate (TOP2A), mapped fission-yeast interactome including monopolin (Pcs1/Mde4) substrates, and showed a disease-associated frameshift variant destabilizes the protein via ubiquitination without affecting intrinsic kinase activity.

    Evidence ChIP/luciferase and in vivo tumor models; TAP-MS and in vitro kinase assays in S. pombe; variant kinase/ubiquitination assays

    PMID:39931818 PMID:40700808 PMID:41216289

    Open questions at the time
    • TOP2A phosphosite not mapped
    • Disease phenotype not characterized beyond protein stability
    • Interactome largely from fission yeast

Open questions

Synthesis pass · forward-looking unresolved questions
  • How CK2's constitutive, broadly distributed activity is spatially and substrate-selectively targeted in mammalian cells — and which substrates underlie its essential viability and neuromuscular functions — remains unresolved.
  • No structural model of substrate recognition in the corpus
  • Essential mammalian substrates undefined
  • Mechanism coupling holoenzyme assembly to substrate choice unknown

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140096 catalytic activity, acting on a protein 6 GO:0016740 transferase activity 4 GO:0140657 ATP-dependent activity 1
Localization
GO:0005634 nucleus 3
Pathway
R-HSA-162582 Signal Transduction 3 R-HSA-74160 Gene expression (Transcription) 3 R-HSA-9612973 Autophagy 2 R-HSA-1430728 Metabolism 1 R-HSA-73894 DNA Repair 1
Partners
AKT1CSNK2BDUSP2HMGA2MAXOGTSIRT6
Complex memberships
CK2 holoenzyme (alpha2beta2)

Evidence

Reading pass · 21 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1988 The CKA1 gene encodes the 42 kDa alpha catalytic subunit of yeast casein kinase II. Null disruption of CKA1 alone produces no detectable phenotype, indicating functional redundancy with the alpha' subunit encoded by CKA2. Gene cloning, sequencing, gene replacement/disruption in S. cerevisiae Molecular and cellular biology High 3062376
1990 CKA1 and CKA2 together are essential for viability in S. cerevisiae; simultaneous deletion of both catalytic subunit genes is lethal. Loss of CKII activity causes cells to arrest with increased size, pseudomycelial morphology, and flocculation. Yeast lacking both subunits can be rescued by Drosophila CK2 alpha subunit alone or alpha+beta, demonstrating conservation of CK2 function across evolution. Gene replacement/disruption double mutant (cka1Δ cka2Δ), phenotypic analysis, cross-species complementation Molecular and cellular biology High 2196445
1992 Casein kinase II forms an alpha2beta2 holoenzyme in vivo. In yeast rescued by Drosophila alpha alone, CK2 activity purifies as a free, catalytically active alpha subunit monomer; in yeast rescued by alpha+beta, it purifies as a mixture of tetrameric holoenzyme and monomeric alpha. Free catalytic subunit (overexpressed 6–18-fold) is not toxic in vivo. Biochemical purification and characterization of CK2 from rescued yeast strains, activity assays The Journal of biological chemistry High 1527008
1998 The CKA1-encoded catalytic subunit has a distinct functional specialization from CKA2: cka1(ts) cka2 strains arrest with a nonpolarized actin cytoskeleton, delocalized chitin deposition, and multinucleate cells, establishing a requirement for CKII (specifically CKA1) in the maintenance of cell polarity in S. cerevisiae. Temperature-sensitive allele construction, conditional growth arrest, actin and chitin staining, cell morphology analysis The Journal of biological chemistry High 9488724
1994 The human CSNK2A1 gene is located on chromosome 20p13. The gene contains at least 8 exons (covering bases 102–824 of the coding region), and introns contain tandemly arranged Alu repeats. Genomic library screening, FISH chromosomal localization, exon/intron mapping Genomics Medium 8188256
1998 The complete human CSNK2A1 gene spans 70 kb, consists of 13 exons, has two transcription start sites, and its 5' promoter region shows housekeeping promoter features (no TATA box, CpG island, GC boxes). Reporter gene assay confirmed promoter activity between positions −256 and +144. Genomic cloning, primer extension, reporter gene assay Genomics Medium 9503018
2011 The yeast CKA2 catalytic subunit phosphorylates C-terminal serines of the E2 ubiquitin-conjugating enzyme tmCdc34, and this phosphorylation prevents the synthesis of free polyubiquitin chains, likely by promoting their attachment to substrate. In vitro kinase assay, genetic epistasis (ubp14Δ, cka2Δ), polyubiquitination assays Cell division Medium 21453497
2015 Yeast CKA2 is required for H2O2-induced apoptosis and high-temperature stress tolerance by regulating NOS-like-dependent nitric oxide (NO) accumulation; Δcka2 mutants show reduced NOS-like activity and reduced NO after H2O2 or high-temperature stress. Yeast deletion mutant (Δcka2), NO measurement, NOS-like activity assay, NO donor rescue experiment FEMS yeast research Medium 26100262
2016 CSNK2A1 (CK2α) physically binds SIRT6 and phosphorylates it in vitro. Phosphorylation of SIRT6 at Ser338 by CSNK2A1 promotes breast cancer cell proliferation and invasiveness, and is required for nuclear β-catenin localization and upregulation of MMP9, β-catenin, cyclin D1, and NF-κB. Co-immunoprecipitation, GST pull-down assay, in vitro kinase assay, immunofluorescence, mutant CSNK2A1/SIRT6 transfection, siRNA knockdown The American journal of pathology High 27746184
2021 CSNK2A1-mediated phosphorylation of SIRT6 at Ser338 activates the DNA damage repair pathway and confers doxorubicin resistance in osteosarcoma cells. Mutation of the SIRT6 Ser338 phosphorylation site attenuates CSNK2A1-mediated doxorubicin resistance in vivo. CSNK2A1 overexpression/knockdown, site-directed mutagenesis of SIRT6 Ser338, in vivo tumor models, Western blot Cells Medium 34359939
2021 CSNK2A1 phosphorylates HMGA2 in a cisplatin-inducible manner. HMGA2 and CSNK2A1 co-localize in the nucleus and interact by co-immunoprecipitation. CX-4945 (CSNK2A1 inhibitor) blocks HMGA2 phosphorylation and sensitizes cervical cancer cells to cisplatin. Liquid chromatography–tandem mass spectrometry, co-immunoprecipitation, immunofluorescence co-localization, kinase inhibitor treatment FEBS open bio Medium 34115920
2022 In S. pombe, the CK2α catalytic subunit Cka1 phosphorylates transcription cofactor PC4. This phosphorylation downregulates PC4's RNA polymerase II coactivator function; the CK2β regulatory subunit (Ckb1) inhibits this phosphorylation. Mutation of both CK2 consensus serine residues in PC4 abolishes phosphorylation and renders PC4 resistant to CK2α-mediated inactivation. In vitro phosphorylation assay, in vitro transcription assay, site-directed mutagenesis of PC4 serine residues International journal of molecular sciences High 36012759
2022 Skeletal muscle-specific conditional knockout of CSNK2A1 in mice results in age-dependent grip strength reduction, impaired neuromuscular transmission, increased regenerating (central-nuclei) fibers, impaired oxidative metabolism with mitochondrial enzyme accumulation, stimulated autophagy, and fragmented neuromuscular junctions with increased synaptic gene expression. Ablation of CSNK2A1 also aberrantly changes protein levels of other CSNK2 subunits. Skeletal muscle-specific Cre-mediated conditional knockout (HSA-Cre), grip strength, electrophysiology, histology, enzyme activity, Western blot Cells High 36552726
2023 CSNK2A1 phosphorylates MAX, shifting MAX-MAX homodimers to C-MYC-MAX and β-catenin-MAX heterodimers. These heterodimers increase HMGB1 and IL-6 promoter activities, promoting cholangiocarcinoma cell proliferation, migration, and invasion. Overexpression, co-immunoprecipitation, promoter activity assays, CK2 inhibitor (CX-4945) treatment, Western blot Hepatology communications Medium 37347224
2023 CSNK2A1 competes with AKT1 to bind DUSP2 (dual-specificity phosphatase 2); this competition inhibits CSNK2A1-mediated phosphorylation of AKT1, promoting apoptosis in pancreatic cancer cells in an ERK1/2-independent manner. Co-immunoprecipitation, competition binding assays, in vitro and in vivo apoptosis assays, knockdown/overexpression Cancer letters Medium 37390887
2024 Cholesterol directly binds to CSNK2A1, augmenting its kinase activity. Activated CSNK2A1 phosphorylates IGF2R at Ser2484, rewiring lipid-driven mitochondrial oxidative phosphorylation and generating reactive oxygen species, creating a positive feedback loop for cholesterol biosynthesis in hepatocellular carcinoma. Proteomics, phosphoproteomics, direct cholesterol-CSNK2A1 binding assay, kinase activity assay, patient-derived cell lines/organoids/xenografts Journal of advanced research Medium 39547439
2024 OGT mediates O-GlcNAcylation of CSNK2A1, enhancing its protein stability. Knockdown of CSNK2A1 suppresses colorectal cancer cell proliferation, migration, invasion, and EMT; OGT overexpression reverses these effects in a CSNK2A1-dependent manner. Co-immunoprecipitation, Western blot, immunofluorescence, siRNA knockdown, in vivo tumor model Molecular biotechnology Medium 38289573
2024 CSNK2A1 activates autophagy in pancreatic cancer cells, driving gemcitabine resistance. H3K27 acetylation mediates transcriptional regulation of CSNK2A1. The CSNK2A1 inhibitor Silmitasertib inhibits autophagy and restores gemcitabine sensitivity in vitro and in patient-derived xenograft models. siRNA knockdown, PDX model, autophagy assays, Silmitasertib pharmacological inhibition, bioinformatic analyses Cancer letters Medium 38290659
2025 SOX4 transcriptionally upregulates CSNK2A1 by binding its promoter. CSNK2A1 in turn phosphorylates TOP2A, promoting breast cancer cell proliferation, migration, invasion, and tumor growth. Silencing SOX4 reduces CSNK2A1 expression and TOP2A phosphorylation. Dual-luciferase reporter assay, chromatin immunoprecipitation (ChIP), Western blot for phosphorylated TOP2A, siRNA knockdown, in vivo mouse tumor models FASEB journal Medium 39931818
2025 In S. pombe, the CK2α catalytic subunit Cka1 physically associates with components of RSC chromatin remodeling complex, Pcs1/Mde4 (monopolin) complex, snoRNA-containing ribonucleoproteins, and spliceosomal machinery. In vitro kinase assays show Cka1 directly phosphorylates Pcs1 and Mde4. RNase-free tandem affinity purification coupled with mass spectrometry, in vitro kinase assay Biochemical and biophysical research communications Medium 40700808
2025 A CSNK2A1 frameshift variant (c.1020_1021delAG, p.Gly342Glnfs*57) does not impair kinase activity in vitro but results in significantly reduced protein expression relative to wild-type, associated with elevated ubiquitination of the mutant protein. In vitro kinase assay, Western blot quantification, ubiquitination assay, overexpression of wild-type and mutant plasmids Frontiers in genetics Medium 41216289

Source papers

Stage 0 corpus · 48 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
1990 Isolation, sequencing, and disruption of the yeast CKA2 gene: casein kinase II is essential for viability in Saccharomyces cerevisiae. Molecular and cellular biology 331 2196445
1988 Isolation, sequencing, and disruption of the CKA1 gene encoding the alpha subunit of yeast casein kinase II. Molecular and cellular biology 115 3062376
2016 CK2α/CSNK2A1 Phosphorylates SIRT6 and Is Involved in the Progression of Breast Carcinoma and Predicts Shorter Survival of Diagnosed Patients. The American journal of pathology 75 27746184
2016 De novo mutations in CSNK2A1 are associated with neurodevelopmental abnormalities and dysmorphic features. Human genetics 73 27048600
2019 Identification of de novo CSNK2A1 and CSNK2B variants in cases of global developmental delay with seizures. Journal of human genetics 64 30655572
1998 Temperature-sensitive mutations of the CKA1 gene reveal a role for casein kinase II in maintenance of cell polarity in Saccharomyces cerevisiae. The Journal of biological chemistry 61 9488724
1992 Purification and characterization of casein kinase II (CKII) from delta cka1 delta cka2 Saccharomyces cerevisiae rescued by Drosophila CKII subunits. The free catalytic subunit of casein kinase II is not toxic in vivo. The Journal of biological chemistry 44 1527008
1994 The human gene (CSNK2A1) coding for the casein kinase II subunit alpha is located on chromosome 20 and contains tandemly arranged Alu repeats. Genomics 43 8188256
2018 Extending the phenotype associated with the CSNK2A1-related Okur-Chung syndrome-A clinical study of 11 individuals. American journal of medical genetics. Part A 35 29383814
1998 Genomic organization and promoter identification of the human protein kinase CK2 catalytic subunit alpha (CSNK2A1). Genomics 31 9503018
2019 CSNK2A1 Promotes Gastric Cancer Invasion Through the PI3K-Akt-mTOR Signaling Pathway. Cancer management and research 28 31819646
2021 Identification of novel CSNK2A1 variants and the genotype-phenotype relationship in patients with Okur-Chung neurodevelopmental syndrome: a case report and systematic literature review. The Journal of international medical research 24 34038195
2023 DUSP2 recruits CSNK2A1 to suppress AKT1-mediated apoptosis resistance under hypoxic microenvironment in pancreatic cancer. Cancer letters 22 37390887
2022 In silico investigations identified Butyl Xanalterate to competently target CK2α (CSNK2A1) for therapy of chronic lymphocytic leukemia. Scientific reports 21 36271116
2020 miR-1184 regulates the proliferation and apoptosis of colon cancer cells via targeting CSNK2A1. Molecular and cellular probes 18 32619668
2024 CSNK2A1 confers gemcitabine resistance to pancreatic ductal adenocarcinoma via inducing autophagy. Cancer letters 17 38290659
2023 The long transcript of lncRNA TMPO-AS1 promotes bone metastases of prostate cancer by regulating the CSNK2A1/DDX3X complex in Wnt/β-catenin signaling. Cell death discovery 16 37542040
2022 Fusogenic peptide delivery of bioactive siRNAs targeting CSNK2A1 for treatment of ovarian cancer. Molecular therapy. Nucleic acids 16 36213692
2021 CK2α/CSNK2A1 Induces Resistance to Doxorubicin through SIRT6-Mediated Activation of the DNA Damage Repair Pathway. Cells 16 34359939
2022 CircNDST1 promotes papillary thyroid cancer progression via its interaction with CSNK2A1 to activate the PI3K-Akt pathway and epithelial-mesenchymal transition. Journal of endocrinological investigation 14 36306106
2022 Predictive functional, statistical and structural analysis of CSNK2A1 and CSNK2B variants linked to neurodevelopmental diseases. Frontiers in molecular biosciences 14 36310603
2023 P300 increases CSNK2A1 expression which accelerates colorectal cancer progression through activation of the PI3K-AKT-mTOR axis. Experimental cell research 11 37391010
2019 [A case of Okur-Chung syndrome caused by CSNK2A1 gene variation and review of literature]. Zhonghua er ke za zhi = Chinese journal of pediatrics 11 31060130
2020 [Identification of a novel de novo variant of CSNK2A1 gene in a boy with Okur-Chung neurodevelopmental syndrome]. Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics 9 32472542
2015 CKA2 functions in H2O2-induced apoptosis and high-temperature stress tolerance by regulating NO accumulation in yeast. FEMS yeast research 9 26100262
2023 CSNK2A1-mediated MAX phosphorylation upregulates HMGB1 and IL-6 expression in cholangiocarcinoma progression. Hepatology communications 8 37347224
2021 CSNK2A1-mediated phosphorylation of HMGA2 modulates cisplatin resistance in cervical cancer. FEBS open bio 8 34115920
2020 Identification of a Novel CSNK2A1-PDGFRB Fusion Gene in a Patient with Myeloid Neoplasm with Eosinophilia. Cancer research and treatment 8 33421986
2011 The loop-less tmCdc34 E2 mutant defective in polyubiquitination in vitro and in vivo supports yeast growth in a manner dependent on Ubp14 and Cka2. Cell division 8 21453497
2024 O-GlcNAcylation of CSNK2A1 by OGT is Involved in the Progression of Colorectal Cancer. Molecular biotechnology 7 38289573
2024 Oncogenic cholesterol rewires lipid metabolism in hepatocellular carcinoma via the CSNK2A1-IGF2R Ser2484 axis. Journal of advanced research 7 39547439
2023 Inherited CSNK2A1 variants in families with Okur-Chung neurodevelopmental syndrome. Clinical genetics 7 37491870
2021 Long non-coding RNA B3GALT5-AS1 contributes to the progression of gastric cancer via interacting with CSNK2A1. Experimental and therapeutic medicine 6 34306196
2023 A Case of Okur-Chung Neurodevelopmental Syndrome with a Novel, de novo Variant on the CSNK2A1 Gene in a Turkish Patient. Molecular syndromology 4 38357263
2024 Comprehensive landscape of gastric cancer-targeted therapy and identification of CSNK2A1 as a potential target. Heliyon 3 39253198
2024 Expanding the phenotypic spectrum of CSNK2A1-associated Okur-Chung neurodevelopmental syndrome. HGG advances 3 39497417
2019 Structural analysis of fungal pathogenicity-related casein kinase α subunit, Cka1, in the human fungal pathogen Cryptococcus neoformans. Scientific reports 3 31591414
1994 PstI identifies biallelic DNA polymorphism of the human casein kinase 2 alpha gene (CSNK2A1). Human genetics 3 7909530
2025 Novel role of the SOX4/CSNK2A1 axis in regulating TOP2A phosphorylation in breast cancer progression. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2 39931818
2025 Clinical and molecular results in 15 Turkish patients with Wiedemann-Steiner syndrome: identification of eight novel KMT2A variants and a case of dual molecular diagnosis in the CSNK2A1. European journal of pediatrics 2 40742416
2025 Ellagic Acid Mediates the Delay of Dermal Fibroblast Senescence via CSNK2A1. Clinical, cosmetic and investigational dermatology 2 40860313
2024 Patient with a heterozygous pathogenic variant in CSNK2A1 gene: A new case to update the Okur-Chung neurodevelopmental syndrome. American journal of medical genetics. Part A 2 38711237
2022 The Catalytic Subunit of Schizosaccharomyces pombe CK2 (Cka1) Negatively Regulates RNA Polymerase II Transcription through Phosphorylation of Positive Cofactor 4 (PC4). International journal of molecular sciences 2 36012759
2022 In Skeletal Muscle Fibers, Protein Kinase Subunit CSNK2A1/CK2α Is Required for Proper Muscle Homeostasis and Structure and Function of Neuromuscular Junctions. Cells 2 36552726
2025 Exploring the Cka1 kinase interactome: unveiling novel potential regulatory roles of CKII kinase in S. pombe. Biochemical and biophysical research communications 1 40700808
2024 A guide to selecting high-performing antibodies for CSNK2A1 (UniProt ID: P68400) for use in western blot, immunoprecipitation and immunofluorescence. F1000Research 1 39403680
2025 Identification and functional analysis of a novel CSNK2A1 frameshift variant in stillbirth. Frontiers in genetics 0 41216289
2025 A Case of CSNK2A1 Gene Variant Causing Okur-Chung Syndrome and Analysis of the Clinical Phenotypic Spectrum. Molecular genetics & genomic medicine 0 41395761

Missed literature

Know a paper Affinage missed for CSNK2A1? Flag it for the maintainers and the community.

No submissions yet.